LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Blueprint Medicines Corp

Suletud

SektorTervishoid

127.83 -0.02

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

127.51

Max

128.01

Põhinäitajad

By Trading Economics

Sissetulek

50M

496K

Müük

3M

149M

Aktsiakasum

-0.294

Kasumimarginaal

0.332

Töötajad

682

EBITDA

-14M

-41M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+1.35% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

31. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

2.5B

8.3B

Eelmine avamishind

127.85

Eelmine sulgemishind

127.83

Uudiste sentiment

By Acuity

32%

68%

87 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Blueprint Medicines Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. juuni 2025, 09:17 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2. juuni 2025, 05:31 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

2. juuni 2025, 13:50 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2. juuni 2025, 10:50 UTC

Omandamised, ülevõtmised, äriostud

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2. juuni 2025, 10:05 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2. juuni 2025, 05:06 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2. juuni 2025, 05:06 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2. juuni 2025, 05:05 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2. juuni 2025, 05:05 UTC

Omandamised, ülevõtmised, äriostud

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2. juuni 2025, 05:04 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2. juuni 2025, 05:04 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

2. juuni 2025, 05:03 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Buy Blueprint Medicines Corporation

2. juuni 2025, 05:02 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Acquire Blueprint Medicines Corporation

Võrdlus sarnastega

Hinnamuutus

Blueprint Medicines Corp Prognoos

Hinnasiht

By TipRanks

1.35% tõus

12 kuu keskmine prognoos

Keskmine 129.63 USD  1.35%

Kõrge 143 USD

Madal 105 USD

Põhineb 20 Wall Streeti analüütiku instrumendi Blueprint Medicines Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

20 ratings

4

Osta

16

Hoia

0

Müü

Tehniline skoor

By Trading Central

87.66 / 99.25Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Strong Bullish Evidence

Sentiment

By Acuity

87 / 380 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.